CIPLA - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 4.0
| Stock Code | CIPLA | Market Cap | 1,13,027 Cr. | Current Price | 1,399 ₹ | High / Low | 1,673 ₹ |
| Stock P/E | 30.5 | Book Value | 423 ₹ | Dividend Yield | 0.93 % | ROCE | 14.7 % |
| ROE | 11.2 % | Face Value | 2.00 ₹ | DMA 50 | 1,328 ₹ | DMA 200 | 1,397 ₹ |
| Chg in FII Hold | -1.38 % | Chg in DII Hold | 1.26 % | PAT Qtr | 385 Cr. | PAT Prev Qtr | 822 Cr. |
| RSI | 61.9 | MACD | 35.5 | Volume | 9,32,429 | Avg Vol 1Wk | 14,18,696 |
| Low price | 1,166 ₹ | High price | 1,673 ₹ | PEG Ratio | 2.32 | Debt to equity | 0.00 |
| 52w Index | 46.0 % | Qtr Profit Var | -69.1 % | EPS | 43.5 ₹ | Industry PE | 30.5 |
📊 Financials: CIPLA has a market cap of 1,13,027 Cr. with quarterly PAT at 385 Cr., down from 822 Cr. (-69.1%). ROE at 11.2% and ROCE at 14.7% reflect moderate efficiency. Debt-to-equity at 0.00 highlights a debt-free balance sheet. EPS of 43.5 ₹ supports earnings visibility, though profit decline is a concern.
💹 Valuation: The stock trades at a P/E of 30.5, equal to the industry average, suggesting fair valuation. P/B ratio is ~3.3 (1399/423), reflecting premium pricing. PEG ratio of 2.32 indicates growth is already priced in. Intrinsic value appears close to current price, offering limited margin of safety.
🏢 Business Model: CIPLA operates in the pharmaceutical sector, benefiting from strong brand presence, diversified product portfolio, and global reach. Its competitive advantage lies in R&D capabilities, regulatory approvals, and consistent demand for healthcare products. However, profitability is pressured by pricing regulations and competition.
📈 Entry Zone: With RSI at 61.9 (slightly overbought), MACD positive, and price near DMA 200 (1397 ₹), accumulation around 1,350–1,400 ₹ looks favorable. Long-term holding is justified given debt-free status, strong brand, and fair valuation, but investors should monitor earnings recovery.
Positive
- 📌 Debt-free balance sheet (Debt-to-equity 0.00).
- 📌 Strong brand presence and diversified portfolio.
- 📌 EPS of 43.5 ₹ supports earnings visibility.
- 📌 Increase in DII holdings (+1.26%) shows domestic institutional confidence.
Limitation
- ⚠️ Quarterly PAT declined sharply (-69.1%).
- ⚠️ ROE at 11.2% and ROCE at 14.7% are moderate.
- ⚠️ PEG ratio of 2.32 suggests growth is fully priced in.
- ⚠️ Dividend yield of 0.93% is modest.
Company Negative News
- ❌ Decline in FII holdings (-1.38%) indicates reduced foreign investor confidence.
Company Positive News
- ✅ Increase in DII holdings (+1.26%) shows strong domestic support.
- ✅ Debt-free operations and strong global presence.
Industry
- 🏦 Pharmaceutical sector benefits from consistent demand and global healthcare expansion.
- 🏦 Industry P/E at 30.5 suggests CIPLA trades at fair value.
Conclusion
🔑 CIPLA is fundamentally stable with debt-free operations, strong brand presence, and fair valuation. Despite profit decline and moderate efficiency metrics, long-term investors may consider entry around 1,350–1,400 ₹ for better risk-reward balance. The company remains a resilient player in the pharmaceutical sector with global growth potential.
For deeper insights, you could explore a peer comparison or a pharmaceutical sector outlook to see how CIPLA stacks up against competitors.